Clinical Trials

Glioblastoma Multiforme (Newly Diagnosed and Recurrent), Anaplastic Astrocytoma (Newly Diagnosed and Recurrent)

• 3D-PREDICT REGISTRY: 3D Prediction of Patient-specific Response Using Ex Vivo Interrogation of Live Cells From Tumors
  (Patient’s live brain tumor cells are grown in a “3D” microenvironment and then tested to assess their response to a number of medical therapies  (results returned as early as 7-10 days). Study is sponsored by KIYATEC Inc.)
  Principle Investigator: Dr. Navid Redjal

Meningiomas

• Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
  (NCI-sponsored randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that have been completely removed by surgery)
  Principle Investigator: Dr. Navid Redjal

Malignant brain tumors (including metastatic brain cancer and gliomas)

• Molecular and biochemical characterization of malignant and metastatic brain tumors. (collaboration with Princeton University)
  (This is a study at Capital Health in collaboration with Princeton university that attempts to further characterize malignant brain tumors (metabolomics, proteomics, RNA expression))
  Principle Investigator: Dr. Navid Redjal
   
• Assessing Quality of Life in Adult Neuro-Oncology Patients after SRS (Stereotactic Radiosurgery)  and WBRT (Whole Brain Radiation Therapy) Treatment, A Prospective Study
  Principle Investigator: Dr. Navid Redjal
   
• Trends and Outcomes in Utilization of SRS and WBRT in Adult Brain Tumor Patients
  Principle Investigator: Dr. Navid Redjal

A011401 – Randomized, Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight Women with Early Breast Cancer
Dr. Rose Mustafa is the principal investigator for this study.

EAY131: Molecular Analysis for Therapy Choice (MATCH) – Patients enrolled in study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment. Patients with hystologically documented solid tumors and lymphomas whose disease has progressed following at least one line of standard systemic therapy or for whom no standard therapy exists will be registered on the screening step to undergo tumor biopsy and analysis.

Circulating tumor DNA exposure in peripheral blood using a novel process: a feasibility study sponsored by Quantgene, Inc. (Dr. Cataldo Doria, PI)

Metabolic gene signatures in tissue biopsies and circulating biomarkers in blood samples of patients with cancer in partnership with the Blumberg Institute (HCC – Dr. Cataldo Doria, PI)

Capital Health Tissue Biorepository (Dr. Krister Jones, PI)

CH Radiation Oncology - Establishing an anticipatory model for anxiety and depression through a screening tool for first time radiation oncology patients (Rona Remstein)

National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstate Value and Sustainability of Navigation Programs (Patricia Tatrai)

Comparison of Upper Extremity Range of Motion in Post-Mastectomy Patients with and without formal mobility exercise education and initiation at time of mastectomy (Dr. Lisa Allen, PI)

Rutgers Cancer Institute of New Jersey – African American Woman’s Circle of Health Breast Cancer Research Study

Dana-Faber/Brigham and Woman’s Cancer Center (Dr. Geoffrey Oxnard) – INHERIT EGFR (Genetic Mutation T790M Lung Registry Study)